Showing results (161-170 of 187) with videos related to
Sort By:
Pageof 19
Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 21, 2026
Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus BevacizumabFujimasa Tada, Atsushi Hiraoka, Hideko Ohama, et al.Hepatology (Baltimore, Md.)|May 6, 2026
Optimizing bevacizumab exposure in atezolizumab-based therapy for unresectable hepatocellular carcinoma: A nationwide real-world studyKaho Aoe, Toshifumi Tada, Atsushi Hiraoka, et al.Oncology|August 3, 2026
Usefulness of the Lymphocyte-to-Monocyte Ratio in Predicting Prognosis in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus BevacizumabEmi Tanaka, Toshifumi Tada, Atsushi Hiraoka, et al.Journal of Gastroenterology and Hepatology|May 23, 2026
Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA TrialTomomitsu Matono, Toshifumi Tada, Atsushi Hiraoka, et al.Liver International : Official Journal of the International Association for the Study of the Liver|July 20, 2026
Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCCKazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 9, 2026
Efficacy and Safety of Atezolizumab Plus Bevacizumab Versus Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma in Patients With Child-Pugh Class B: A Real-World StudyHideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.Liver Cancer|June 3, 2026
Real-World Comparison of First-Line Atezolizumab plus Bevacizumab and Durvalumab plus Tremelimumab for Unresectable Hepatocellular CarcinomaAtsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, et al.Eclinicalmedicine|August 20, 2025
Impact of metabolic dysfunction on treatment responses to nucleos(t)ide analogues in chronic hepatitis B: a retrospective multi-center REAL-B cohort studyRui Huang, Dae Won Jun, Hidenori Toyoda, et al.Clinical and Molecular Hepatology|March 17, 2025
Impact of components of metabolic syndrome on long-term outcomes of CHB with nucleos(t)ide analogue treatmentRui Huang, Dae Won Jun, Hidenori Toyoda, et al.Journal of Viral Hepatitis|September 13, 2025
Impact of Concurrent Steatotic Liver Disease and Chronic Hepatitis B on Treatment Response to Nucleos(t)ide AnalogsAngela Chau, Jie Li, Dae Won Jun, et al.Pageof 19